Latest filing published 01 Mar 2021 for Altimmune, Inc., €80k.
Filing timeline
BuySaleInsider track record
Philip Hodges: trading record in brief
Philip Hodges discloses dealings in Altimmune, Inc. to SEC (Form 4). Between 4 May 2017 and 1 March 2021, the trades on record add up to 8 filings.
No open-market purchase appears, only 3 sales worth €119k. Outside the open market, there are 3 share grants and 1 option exercise. Since January 2021: no purchases and 1 sale on the market.
The newest entry dates from 1 March 2021: an open-market sale of €80k, in Altimmune, Inc. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Philip Hodges
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,000 shares@ US$16.0867.2% of flowCommon Stock, par value $0.0001SEC:0000899243-21-008691:0
- 2,500 shares@ US$12.0064.3% of flowCommon Stock, par value $0.0001SEC:0000899243-20-032576:0
- 1,227 shares@ US$13.5435.7% of flowCommon Stock, par value $0.0001SEC:0000899243-20-032576:1
- 16,850 shares0Common Stock, par value $0.0001SEC:0000899243-20-028535:0
- 1,278,471 shares0Common Stock, par value $0.0001SEC:0001012975-17-000759:0
- 1,278,471 sharesCommon Stock, par value $0.0001SEC:0000899243-17-012362:0
- 36,785 sharesCommon Stock, par value $0.0001SEC:0000899243-17-012362:1
- 4,455 sharesCommon Stock, par value $0.0001SEC:0000899243-17-012362:2
8 of 8 declarations
